Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Seborrhoeic dermatitis

Also known as: seborrheic dermatitis, seborrhoeic eczema, seborrheic eczema, dandruff

Seborrhoeic dermatitis is a common inflammatory skin condition that causes flaky patches, often on the scalp, eyebrows, beside the nose and around the ears. It tends to come and go. Medical treatment and suitable skincare can help control the rash and discomfort.

In plain English — This condition causes recurring flaky patches, especially on the scalp and central face. Antifungal treatments and medicines that calm inflammation can help control it. Gentle cleansing and a comfortable moisturiser can support the treatment plan.

Evidence status

Strong

Established condition; treatment supported by clinical trials. Clinical references describe a recognisable relapsing disorder, with randomised evidence for topical antifungal and anti-inflammatory medicines. The major Cochrane reviews mainly concern short-term adolescent/adult face and scalp treatment; newer roflumilast trials concern a specific medicinal formulation. Selection depends on diagnosis, body site, age, tolerance and the need for continuing control.

What seborrhoeic dermatitis is and how it presents#

Seborrhoeic dermatitis is a relapsing inflammatory condition in areas rich in sebaceous glands. Common locations include the scalp, eyebrows, sides of the nose, beard and ears; the central chest and body folds can also be involved. Scale may look greasy or dry, and itch varies. Changes may be red, lighter or darker than the surrounding skin, so colour alone is an incomplete guide to activity.[1, 2, 3][1, 2, 11]

Dandruff is the mild scalp end of this presentation, with little or no visible inflammation. Infantile seborrhoeic dermatitis, often called cradle cap, usually has a different course and commonly settles during infancy. The focus here is the adolescent/adult disorder relevant to aesthetic consultations.[1, 2, 11]

Diagnosis is usually clinical. The pattern may resemble, or coexist with, psoriasis, rosacea or contact dermatitis. The overlap with psoriasis is sometimes called sebopsoriasis. Suspected scalp ringworm or an uncertain eruption can require targeted clinical investigation.[1, 2, 3, 11]

Use of seborrhoeic dermatitis in aesthetic practice#

Recognising a recurring scalp-and-face pattern helps prevent a consultation being reduced to separate complaints about “dry skin”, flakes or redness. A useful record brings together the affected sites, symptoms, previous diagnoses, treatment response and current medicines. Supportive skincare can then fit around the clinical plan.[1, 3]i

The working priorities are comfort, gentle cleansing and an acceptable moisturiser, alongside the person’s prescribed or pharmacist-guided care. The skin barrier entry explains function; impaired skin barrier explains a state that can accompany several diagnoses. Neither replaces assessment of this particular condition.[1, 4, 5]

Contraindications and cautions#

An unexplained active rash needs assessment before elective work that could add irritation to the affected skin. Once the diagnosis and care plan are established, site, symptoms and tolerance guide what supportive care is appropriate.[1, 3]i

Medicine cautions are formulation-specific. For example, the retained Nizoral 2% Cream prescribing information is for an adult prescription medicine: ingredient hypersensitivity is a contraindication, it is not an eye preparation, and safety and efficacy in people 17 or younger are not established in that label. This does not describe every ketoconazole formulation.[6]

Pregnancy advice also belongs to the actual medicine. That cream’s label reports no known pregnancy or lactation risks, while acknowledging limited exposed-pregnancy data and no adequate controlled studies. Its absorption statement comes from topical use in non-pregnant adults. A clinician or pharmacist can apply those product-specific facts to the individual; the statement is not interchangeable with oral antifungal safety.[6]

Clinical uses and the evidence behind them#

Topical antifungals

A 2015 Cochrane review, searching to December 2014, included 51 studies and 9,052 adolescents/adults with face or scalp disease.[4]At about four weeks, studied ketoconazole 2% preparations reduced failure to achieve complete clearance versus placebo: risk ratio 0.69 (95% CI 0.59–0.81; eight studies, 2,520 participants; low-quality evidence).[4]For ciclopirox 1%, the corresponding failed-remission estimate was 0.79 (95% CI 0.67–0.94; eight studies; moderate-quality evidence). These are relative risks of persistent disease, not percentages of people cured. The review identified potential conflicts, including pharmaceutical involvement, in 24 trials.[4]

Anti-inflammatory medicines

The companion 2014 review included 36 trials and 2,706 participants older than 16 with facial or scalp disease; most studies lasted no more than four weeks. Steroid versus azole total-clearance results were RR 1.11 (95% CI 0.94–1.32; eight trials, 464 participants; moderate-quality evidence): a clear difference was not established. The review had institutional support; one reviewer disclosed unrelated pharmaceutical research/consultancy interests.[5]

Newer targeted topical treatment

The manufacturer-sponsored STRATUM trial studied roflumilast foam 0.3%, a phosphodiesterase-4 inhibitor. It enrolled 457 participants, with eligibility from age nine and moderate-or-worse disease at scalp, face, trunk or fold sites. At eight weeks, 79.5% of the active group versus 58.0% of the vehicle group achieved investigator-rated clear/almost clear skin plus at least a two-point improvement (P<.001). Arcutis sponsored the trial and employed several authors. This is evidence for that studied medicine, not a claim about its current availability in UK practice.[9, 10]

Selecting care for seborrhoeic dermatitis#

The clinical choice follows the affected site and the main problem: inflammation, itch, adherent scale, recurring flares or several together. Scalp preparations need to suit hair-bearing skin; facial and fold treatment needs its own tolerability assessment. A familiar ingredient name does not make the vehicles interchangeable.[1, 3, 6]

Clinicians may use an antifungal, an anti-inflammatory medicine or a combination appropriate to the presentation. Scale-softening preparations can have a role on the scalp. That clinical use is distinct from a cosmetic acid peel over an inflamed face. Repeated facial steroid use is a reason for the prescriber to review the strategy, including suitable alternatives.[1, 3, 6]

Adverse effects and their management#

Burning, itch or a new rash can reflect treatment intolerance as well as active disease. The Nizoral cream label records local reactions and contact dermatitis, including possible reactions to excipients. The product and timing of symptoms matter when a clinician or pharmacist assesses the problem.[2, 3, 6]

Facial corticosteroids have a useful medical role, but inappropriate prolonged exposure can cause skin thinning or visible vessels. The choice and duration remain with the clinician. Increasing scale, oozing or crusting, especially around the ears, can also need reassessment for secondary infection.[2, 3, 6]

Referral and scope boundaries#

A GP or suitably qualified clinician can usually assess a typical presentation. Review is particularly valuable when the eruption is extensive, unusual, recurrent despite appropriate care or slow to respond as expected. PCDS advises secondary-care referral for inadequate response. An uncertain diagnosis may call for fungal testing or, less commonly, biopsy.[1, 3]

Severe, widespread or treatment-resistant disease can also prompt assessment for an underlying condition. This may include clinician-led HIV testing where appropriate. Most people with seborrhoeic dermatitis do not have an associated underlying illness; appearance alone is not a basis for an aesthetic practitioner to suggest a specific systemic diagnosis.[1, 3]

Lid-margin scale can accompany blepharitis. Persistent eyelid symptoms need clinical review, while eye pain, vision change or very red eyes need urgent GP/111 assessment. Face creams must not be substituted for an eye treatment.[6][7]

Mechanism of action#

The relevant mechanism is the interaction between normal skin organisms, sebum, barrier properties and host inflammation. Malassezia yeasts can act on skin lipids, producing substances proposed to contribute to irritation in susceptible skin. Differences in the barrier and inflammatory response help explain why a common skin organism does not produce the same clinical picture in everyone. The complete causal pathway remains under investigation.[1, 2, 3]

Antifungal medicines and anti-inflammatory medicines address different aspects of this process. Their clinical usefulness is established through patient outcomes, rather than requiring a practitioner to infer disease severity from oiliness alone.[1, 4, 5]

Commonly misstated claims#

Malassezia and clinical diagnosis

Claim heard:“Finding Malassezia on the skin proves seborrhoeic dermatitis.”

Literature finding: Malassezia can be present on normal skin. DermNet therefore distinguishes identifying the organism from making the clinical diagnosis, which depends on the eruption’s appearance, distribution and course.[2]

Supported statement: A positive finding for a normal skin organism is not a stand-alone diagnostic test.

Dietary associations

Claim heard:“The fruit study proves a dietary cure.”

Literature finding: Sanders and colleagues assessed diet and skin findings in 4,379 Rotterdam Study participants, 636 of whom had seborrhoeic dermatitis. A fruit dietary pattern was associated with lower odds of the condition (adjusted OR 0.76, 95% CI 0.58–0.97), but this was a cross-sectional analysis rather than a treatment trial. One author worked for Unilever, which also appears in the indexed funding record.[8]i

Supported statement: An observed dietary association does not demonstrate that changing diet treats a flare.

Clearance and remission

Claim heard:“Clear at the end of the study means cured for good.”

Literature finding: Trials measure outcomes at defined visits. In the antifungal review, 45 of 51 studies assessed outcomes within five weeks; STRATUM’s primary comparison was at eight weeks. Those observations can establish short-term benefit without establishing permanent remission.[4, 5, 9, 11]i

Supported statement: Clearance and its duration are separate outcomes.

Areas of remaining uncertainty#

  • The best continuing strategy for a particular person’s recurrent disease is not settled by one short treatment comparison; ongoing clinical review remains useful.[4][5]
  • Choosing between finished formulations involves comfort, body site and adherence as well as ingredient identity; a class-wide efficacy ranking does not answer all those practical questions.[4]
  • The mixture of yeast-related, barrier and host factors differs between individuals; commercial tests or explanatory labels should not displace clinical assessment.[1, 2, 3][2]

Frequently asked questions#

Can it affect the face as well as the scalp?

Yes. The eyebrows, skin beside the nose, beard and ears are typical facial sites; scalp involvement can provide useful context for assessment.[1, 2, 11]

Is it contagious?

No. Seborrhoeic dermatitis is not passed from one person to another.[11]

Can someone have it alongside rosacea?

Yes. Coexisting conditions can require a plan that addresses each part of the presentation.[1, 2, 3, 11]

What information helps at a consultation?

A record of affected areas, symptoms, current products and medicines, and the response to previous care gives the clinician a clearer picture of the course.[1, 3]i[4, 5, 9, 11]i

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. British Association of Dermatologists. Seborrhoeic dermatitis. Patient information leaflet. Updated January 2023.Tier 4Supports: Complete public HTML personally retrieved 16 September 2026. Clinical pattern, adult/infant distinction, supportive care, clinical assessment and selected investigations. Page expressly states representative consensus. Inconsistent next-review date retained as a source limitation, not treated as a 2026 update. Medication lists and protocols are not copied wholesale.Funding / interest: BAD institutional consensus patient information; no article-specific manufacturer sponsor declaration located.
  2. Bholah NG, Oakley A, Gomez J. Seborrhoeic dermatitis. DermNet. March 2022; minor update July 2024.Tier 4Supports: Complete clinical body retrieved. Sebaceous-site distribution, morphology, colour variation, differential, Malassezia/barrier hypotheses and the limited diagnostic value of detecting a normal skin organism. Named-author narrative, not a formal systematic review.Funding / interest: DermNet reference; no article-specific funding or author conflict statement located. The website displays advertising.
  3. Primary Care Dermatology Society. Seborrhoeic eczema (syn. seborrhoeic dermatitis). Clinical guidance. Updated 22 February 2024.Tier 4Supports: Full clinical guidance and sponsor footer retrieved. Distribution, psoriasis overlap, clinician-directed face/scalp treatment, limited facial steroid use, recalcitrant/widespread disease and secondary-care referral. HIV assessment is presented as a medical decision, not an aesthetic diagnostic inference.Funding / interest: PCDS lists pharmaceutical sponsors and states they had no involvement in website content or conference programmes. No article-specific funding declaration located; lead author Dr Tim Cunliffe.
  4. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015;(5):CD008138. doi:10.1002/14651858.CD008138.pub3. PMID:25933684.Tier 1Supports: Primary review abstract, summary-of-findings and declarations retrieved through PMC/Europe PMC XML; current bibliographic record confirmed through MEDLINE. Searches to December 2014; adolescent/adult face/scalp disease; 51 studies/9,052 participants. Ketoconazole and ciclopirox failed-clearance endpoints, CIs and GRADE retained. The older PMC4448221 XML bears pub2 despite sharing the PMID; final citation uses confirmed pub3/PMC7177303.Funding / interest: Review support: Nigerian Branch of South African Cochrane Centre and NIHR support for Cochrane Skin Group. All review authors declared nothing; clinical referee Rod Hay disclosed paid P&G/L'Oréal pathogenesis consultancy. Review identified potential conflicts, including pharmaceutical involvement, in 24 included trials.
  5. Kastarinen H, Oksanen T, Okokon EO, Kiviniemi VV, Airola K, Jyrkkä J, Oravilahti T, Rannanheimo PK, Verbeek JH. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014;(5):CD009446. doi:10.1002/14651858.CD009446.pub2. PMID:24838779.Tier 1Supports: Cochrane complete abstract and PMC summary-of-findings/declarations directly retrieved. Search to September 2013; 36 RCTs/2,706 people, adults or adolescents older than 16, face/scalp. Most studies four weeks or less. Steroid versus azole short-term clearance estimate and moderate certainty retained; no claim of demonstrated therapeutic equivalence.Funding / interest: Institutional support included Finnish Medicines Agency, Finnish Institute of Occupational Health, Cochrane groups and NIHR. One reviewer declared unrelated AstraZeneca research and ESiOR consultancy payments (declaration initials PP in source); others declared no interests. Individual trial independence is not assumed.
  6. Thornton & Ross Ltd. Nizoral 2% Cream: Summary of Product Characteristics. emc. Updated 14 May 2024.Tier 1Supports: Product-specific prescribing information personally retrieved. POM, adult use, seborrhoeic dermatitis indication, ingredient hypersensitivity, non-ophthalmic use, pregnancy evidence limitations and adverse reactions. No regimen copied. Unrelated athlete's-foot efficacy study is not used as seborrhoeic-dermatitis evidence.Funding / interest: Manufacturer/marketing-authorisation-holder regulatory information supplied by Thornton & Ross Ltd, not an independent trial.
  7. NHS. Blepharitis. Reviewed 12 June 2025.Tier 4Supports: Full official page retrieved. Eyelid symptoms and relationship to seborrhoeic dermatitis; GP review for persistence and urgent assessment for eye pain, vision change or very red eyes.Funding / interest: NHS institutional patient guidance; not a manufacturer source.
  8. Sanders MGH, Pardo LM, Ginger RS, Kiefte-de Jong JC, Nijsten T. Association between Diet and Seborrheic Dermatitis: A Cross-Sectional Study. J Invest Dermatol. 2019;139(1):108–114. doi:10.1016/j.jid.2018.07.027. PMID:30130619.Tier 3Supports: Primary MEDLINE abstract, affiliations and funding-index record retrieved via Europe PMC. Rotterdam Study skin examinations and food-frequency questionnaires: 4,379 participants, 636 with SD. Fruit-pattern adjusted odds ratio 0.76, 95% CI 0.58–0.97 for reported quartile comparison. Cross-sectional association, not a fruit-treatment trial. Full paper not retrieved; no age distribution, dietary dose or follow-up benefit invented.Funding / interest: Co-author Rebecca S. Ginger was affiliated with Unilever R&D. Indexed funding names Unilever alongside Dutch academic/public institutions and European Commission; full grant roles and conflict statement not retrieved. Manufacturer authorship is disclosed in prose.
  9. Blauvelt A, Draelos ZD, Stein Gold L, et al. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial. J Am Acad Dermatol. 2024;90(5):986–993. doi:10.1016/j.jaad.2023.12.065. PMID:38253129.Tier 2Supports: Primary abstract and author affiliations personally retrieved via Europe PMC. Eight-week STRATUM trial; IGA success defined as clear/almost clear plus at least two-point improvement: 79.5% versus 58.0%, P<.001. Full article/CI not retrieved. Trial registry retained separately for actual enrollment, eligibility, anatomical sites and sponsor. No claim about current UK availability.Funding / interest: Manufacturer-authored: six named authors affiliated with Arcutis Biotherapeutics. STRATUM sponsor Arcutis confirmed in retained source 10. Full individual author disclosures not retrieved.
  10. Arcutis Biotherapeutics, Inc. STRATUM: NCT04973228, ARQ-154-304. ClinicalTrials.gov trial record. Accessed 16 September 2026.Tier 4Supports: Official registry API directly retrieved at /api/v2/studies/NCT04973228. Actual enrollment 457; eligibility age 9 or older, at least moderate disease, scalp/face/trunk/intertriginous involvement permitted, eight-week vehicle-controlled design. Used for design and sponsorship, not as a separate replication of efficacy.Funding / interest: Sponsor and responsible party: Arcutis Biotherapeutics, Inc.; sponsor-submitted registry record.
  11. American Academy of Dermatology. Seborrheic dermatitis: Overview. Written by Paula Ludmann; reviewed by Spearman, Kaye and Peebles. Updated 6 December 2022.Tier 4Supports: Directly retrieved public guidance. Dandruff/inflammation distinction, infant/adult course, possible coexisting rosacea or psoriasis and non-contagious nature. US clinical information is not used to establish UK medicine or practitioner regulation.Funding / interest: AAD institutional patient information; no article-specific funding or reviewer conflict record located.